| Application no. and date | 17708341.7 (espacenet) (Federated) (European Patent Register), 20170220 | | Patent/reg. no. and date | DK/EP 3419624, 20210113 | | Publication date | 20190102 | | Priority no. and date | US 201662298113 P, 20160222 | | EP pub. no. and date |
EP 3419624 20190102 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | BT/GP/164053 | | Inventor | LAFFITTE, Bryan, c/o Novartis Institute for Functional Genomics Inc.
dba The Genomics Institute of the Novartis
Research Foundation (GNF)
10675 John Jay Hopkins Drive
San Diego, California 92121, US,
BADMAN, Michael, c/o Novartis Institutes for
BioMedical Research Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US,
LINDGREN, Sam, c/o Novartis Pharma AG
Postfach
4002 Basel, CH,
CHEN, Jin, c/o Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, New Jersey 07936-1080, US | | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K | | Opponent | | | IPC Class | A61K 31/46 (2006.01) , A61K 31/4748 (2006.01) , A61K 31/497 (2006.01) , A61K 31/506 (2006.01) , A61P 1/00 (2006.01) , A61P 1/16 (2006.01) | | Title | FREMGANGSMÅDER TIL ANVENDELSE AF FXR-AGONISTER | | Int. application no. | IB2017050962 | | Int. publication no. | WO2017145040 | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
